Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Brondfield, Samuel Craig
Weinberg, Vivian K.
Koepfgen, Kathryn M.
Molina, Arturo
Ryan, Charles J.
Small, Eric Jay
Harzstark, Andrea Lynne
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] OrthoBiotech Oncol Res & Dev, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15137
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)
    Brondfield, Samuel Craig
    Weinberg, Vivian K.
    Koepfgen, Kathryn M.
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric Jay
    Harzstark, Andrea Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [2] Effects of abiraterone acetate and enzalutamide on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)
    Ileana, Ecaterina
    Antoun, Sami
    Albiges, Laurence
    Massard, Christophe
    Di Palma, Mario
    Escudier, Bernard J.
    Fizazi, Karim
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Indicators of clinical response to abiraterone acetate (AA) men with metastatic castration-resistant-prostate-cancer (mCRPC).
    Boegemann, Martin
    Mikah, Phillip
    Eminaga, Okyaz
    Herrmann, Edwin
    Papavassills, Philipp Marius
    Semjonow, Axel
    Krabbe, Laura-Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
    Yang, Lily P. H.
    DRUGS, 2011, 71 (15) : 2067 - 2077
  • [5] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [6] Optimal sequencing of enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC)
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa Maria
    Bassi, Sunakshi
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [7] Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC)
    Slovin, Susan F.
    Knudsen, Karen E.
    Halabi, Susan
    Fleming, Mark T.
    Molina, Ana M.
    Wolf, Steven Paul
    de Leeuw, Renee
    Fernandez, Celina
    Kang, Praneet
    Southwell, Traci
    Jones, Carol L.
    Fernandez, Escarleth
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [8] ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    de Boer, Carla
    Todd, Mary
    Yu, Margaret K.
    Scher, Howard I.
    CANCER RESEARCH, 2014, 74 (19)
  • [9] Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience
    Leibowitz-Amit, Raya
    Atenafu, Eshetu G.
    Seah, Jo-An
    Templeton, Arnoud J.
    Vera-Badillo, Francisco Emilio
    Solow, Henry L.
    Knox, Jennifer J.
    Sridhar, Srikala S.
    Tannock, Ian
    Joshua, Anthony Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [10] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345